“These new additions to our control team will provide an essential recommendation as we develop the complex clinical progression of AT-527 as a remedy for COVID-19”, Said Jean-Pierre Sommadossi, Ph. D. , founder, president and CEO of Atea: “Together, the clinical experience and delight of Arantxa and Mihaela will be invaluable as we move forward in our existing systems and expand our portfolio of direct-acting oral antivirals to combat serious viral infections. “
Dr. Horga is an expert in the progression of drugs for infectious diseases with more than 15 years of experience in biopharmacy, adding leading programs for clinical progression, clinical operations and pharmacovigilance. She joined Atea after leaving Biohaven Pharmaceuticals, where she served as Vice President of Pharmacovigilance and Medical Affairs. Previously, she was at Hoffmann-La Roche, where she held the positions of Vice President, Global Director of Clinical Program Execution, Site Director of the Roche NY Innovation Center and Global Director of Translational Medicine, Infectious Diseases. discovery and progression at Bristol-Myers Squibb, where she held various clinical leadership positions as group director, global clinical research, virology. She holds a doctorate in medicine from the Faculty of Medicine of Santander and finished her residency in pediatrics and her specialization in pediatric infectious diseases at the Faculty of Medicine of Mount Sinai, where she remained as a teacher. During his educational mandate, his NIH-funded laboratory studies focused on the mechanisms of respiratory virus pathogenesis.
Dr. MacNair joins Atea from Biogen, where she served as Senior Director of Global Regulatory Affairs and Regulatory Therapeutics, Covering Neurodegenerative and Neuromuscular Diseases. Beginning her career in the pharmaceutical industry in the EU, Dr. MacNair has sought opportunities in the United States, where she has held positions of expanding global responsibility with pharmaceutical corporations such as Vertex Pharmaceuticals, Alkermes and Shire (now Takeda Pharmaceuticals).
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and progression of treatments to address the unmet medical wishes of patients with serious viral diseases. Our main systems are aimed at the progression of direct-acting oral antivirals for the treatment of COVID-19 patients in hospital and network settings, the treatment of patients with chronic hepatitis C, the treatment of dengue patients and the treatment of high. -Risk patients with severe infection by respiratory syncytial virus. Our expertise in medical chemistry, virology, and pharmacology, reinforced through our collective delight in drug progression, enables us to pioneer new advancements in antiviral science. By leveraging the strength of our purine nucleotide prodrug platform, we aim to promote new drug applicants with optimal cure profiles for viral RNA targets. Founded through its president and CEO, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is based in Boston, MA. For more information about Atea and our portfolio of product applicants, please visit our online corporate page at ateapharma. com.
contacts
Investors: Will O’ConnorStern Investor Relations 212-362-1200will. oconnor@sternir. com